TPB Stock Forecast & Price Target

Turning Point Brands is positioned for attractive fundamental upside as modern oral nicotine continues to outperform, with FRE and ALP driving a forecasted rise in modern oral revenue to $223 mm in 2026 and $271 mm in 2027. Its expanding presence in large chains like Circle K and testing in 7-Eleven supports a broader distribution network effect, while slot fees should normalize as scale improves and smaller retailers offer better economics. Despite near-term EBITDA pressure from investment spending and onshoring delays, the stock already appears to discount these headwinds, with solid cash flow, high-single-digit-plus top-line growth, and stronger leverage potential as gross profit inflects.

Turning Point Brands is facing a negative setup because its core tobacco categories are exposed to structural volume declines, intense competition from larger players, and regulatory and litigation risks that could pressure both revenue and margins. The bear case also assumes modern oral nicotine fails to sustain its initial distribution gains, free from expansion cannibalizes DTC sales, and FRE underperforms at retailers, which could lead to slower growth and weaker shelf support. With EBITDA forecast at $78 million in 2026 and $96.5 million in 2027 under continued elevated investment spending, higher slot fees, and no PMTA approval, downside to earnings remains significant.